Castel V, García-Miguel P, Melero C, Navajas A, Navarro S, Molina J, Badal M D, Ruiz-Jimenez J I
Pediatric Oncology Unit, Hospital Infantil, Valencia, Spain.
Eur J Cancer. 1995;31A(4):642-5. doi: 10.1016/0959-8049(95)00072-q.
The Spanish Neuroblastoma Study Group has conducted a study on advanced neuroblastoma (N-I-87), which included 33 stage III and 60 stage IV neuroblastoma children more than 1 year of age, enrolled between October 1987 and April 1992. They were staged according to Evans and treated with induction chemotherapy (IC) consisting of 3 courses of cyclophosphamide-doxorubicin alternating with 3 of high-dose cisplatin-teniposide. Evaluation after IC and surgery demonstrated an overall response rate of 88% for stage III and 69% for stage IV. In the latter, complete responses and good partial responses were 33 and 14%, respectively. After surgery, children received maintenance chemotherapy (all stage III except 2 and 30 stage IV) or autologous bone marrow transplantation (ABMT) (11 stage IV), the distribution was not randomised. Probability of survival at 5 years was 0.60 +/- 0.12 for stage III and 0.24 +/- 0.07 for stage IV. A significant difference in survival at 5 years was found between "good responders" and "non-responders" to initial chemotherapy.
西班牙神经母细胞瘤研究小组开展了一项针对晚期神经母细胞瘤的研究（N-I-87），该研究纳入了1987年10月至1992年4月期间登记的33例III期和60例IV期、年龄超过1岁的神经母细胞瘤患儿。他们按照埃文斯分期法进行分期，并接受了诱导化疗（IC），诱导化疗由3个疗程的环磷酰胺-阿霉素与3个疗程的高剂量顺铂-替尼泊苷交替组成。诱导化疗和手术后的评估显示，III期的总体缓解率为88%，IV期为69%。在IV期患儿中，完全缓解率和良好部分缓解率分别为33%和14%。手术后，患儿接受维持化疗（除2例和30例IV期外的所有III期患儿）或自体骨髓移植（ABMT）（11例IV期患儿），分配并非随机进行。III期患儿5年生存率为0.60±0.12，IV期为0.24±0.07。对初始化疗的“良好缓解者”和“无缓解者”之间发现了5年生存率的显著差异。
